Efficacy of Fecal microbiota transplant in treating patients with active ulcerative colitis with cytomegalovirus infection

Efficacy of FMT in treating patients with active ulcerative colitis with CMV infection: a randomised placebo controlled trial - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/081767

Enrollment

Registered

2025-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B259- Cytomegaloviral disease, unspecified Health Condition 2: K519- Ulcerative colitis, unspecified

Interventions

Intervention1: Fecal Microbiota Transplant: FMT administered at 0, 1 week Control Intervention1: Sham: Sham administered at 0, 1 week

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of active Ulcerative Colitis 2. With presence of CMV Infection 3. Age 18-70yrs

Exclusion criteria

Exclusion criteria: 1. Acute Severe Ulcerative Colitis 2. Patients with surgical intervention for IBD, on psychiatric medication or pregnant and lactating women 3. Patients with Severe comorbid medical illness

Design outcomes

Primary

Measure	Time frame
Clinical responseTimepoint: At 4 weeks	—

Secondary

Measure	Time frame
Clinical remissionTimepoint: 4 weeks;Endoscopic responseTimepoint: 4 weeks;Biochemical remissionTimepoint: 4 weeks;Virologic responseTimepoint: 4 weeks;Adverse eventsTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactAnchit Raj Singh

AIIMS , New Delhi

vineet.aiims@gmail.com9810707170

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026